Target intelligence / Profile preview

Gut mucosal surfaces and resident gut microbiota

Molecular classification
Other
01

Overview

The gut mucosal surfaces and resident gut microbiota constitute a complex biological system rather than a single molecular target. The mucosal surface includes the intestinal epithelium and a protective mucus layer that acts as a selective barrier, facilitating nutrient uptake while preventing the entry of harmful pathogens (Source: NIH/NCBI). The resident microbiota consists of trillions of microorganisms, including bacteria, fungi, and viruses, which play critical roles in fermenting dietary fibers, synthesizing essential vitamins like B12 and K, and modulating the host's innate and adaptive immune systems (Source: Nature Reviews Microbiology). Disruptions to this ecosystem, often termed dysbiosis or increased intestinal permeability, are linked to various pathologies such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and metabolic syndrome (Source: Science). Therapeutic strategies targeting this environment include the use of probiotics, prebiotics, and fecal microbiota transplantation (FMT) to restore microbial equilibrium and enhance barrier function (Source: Gastroenterology). Because this entry describes an entire anatomical and ecological niche rather than a specific protein or receptor, it is classified as a system-level therapeutic site.

Other names
Intestinal mucosal barrierGut microbiomeCommensal gut floraGastrointestinal ecosystemGut-associated lymphoid tissue (GALT)
02

Mechanism of action

Modulation of microbial diversity, restoration of epithelial barrier integrity, competitive exclusion of pathogens, and regulation of mucosal immune signaling.

03

Biological functions

Immune responseNutrient absorptionMetabolic regulationPathogen defenseBarrier function
04

Disease associations

InflammationInfectionCancerMetabolic diseaseAutoimmune disease
05

Safety considerations

DysbiosisSystemic translocation of commensalsTransfer of antibiotic resistance genesImmunosuppression-related infections
06

Interacting drugs

Rifaximin

4 more in the full profile.

07

Biomarkers

Fecal calprotectinZonulinShort-chain fatty acids (SCFAs)Microbial alpha diversitySecretory IgA

Beyond the preview

Go deeper on Gut mucosal surfaces and resident gut microbiota.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut mucosal surfaces and resident gut microbiota.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call